

2. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. *Arch Neurol* 2004;61:661–666.
3. Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. *Arch Intern Med* 2000;160:174–180.
4. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. *Neurology* 1999;53:1937–1942.
5. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. *Diabetes* 2002;51:1256–1262.
6. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. *Dement Geriatr Cogn Disord* 2002;14:77–83.
7. Schnaider Beeri M, Goldbourt U, Silverman JM, et al. Diabetes mellitus in midlife and the risk of dementia three decades later. *Neurology* 2004;63:1902–1907.
8. Haan MN. Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. *Nat Clin Pract Neurol* 2006;2:159–166.
9. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. *Neurology* 1995;45:1161–1168.
10. Kuusisto J, Koivisto K, Mykkanen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. *BMJ* 1997;315:1045–1049.
11. Razay G, Wilcock GK. Hyperinsulinaemia and Alzheimer's disease. *Age Ageing* 1994;23:396–399.
12. Stolk RP, Breteler MM, Ott A, et al. Insulin and cognitive function in an elderly population: The Rotterdam Study. *Diabetes Care* 1997;20:792–795.
13. Peila R, Rodriguez BL, White LR, Launer LJ. Fasting insulin and incident dementia in an elderly population of Japanese-American men. *Neurology* 2004;63:228–233.
14. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. *Neurology* 2004;63:1187–1192.
15. Whitmer RA. Type 2 diabetes and risk of cognitive impairment and dementia. *Curr Neurol Neurosci Rep* 2007;7:373–380.
16. Stozicka Z, Zilka N, Novak M. Risk and protective factors for sporadic Alzheimer's disease. *Acta Virol* 2007;51:205–222.
17. Katsuki S. Epidemiological and clinicopathological study on cerebrovascular disease in Japan. *Prog Brain Res* 1966;21:64–89.
18. Fujimi K, Sasaki K, Noda K, et al. Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: the Hisayama Study. *Brain Pathol* 2008;18:317–325.
19. Ohmura T, Ueda K, Kiyohara Y, et al. Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in the Japanese general population: the Hisayama Study. *Diabetologia* 1993;36:1198–1203.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412–419.
21. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II: standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991;41:479–486.
22. Braak H, Alafuzoff I, Arzberger T, Kretschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol* 2006;112:389–404.
23. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 1991;82:239–259.
24. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. *J Alzheimers Dis* 2006;9:151–153.
25. Frame S, Zheleva D. Targeting glycogen synthase kinase-3 in insulin signalling. *Expert Opin Ther Targets* 2006;10:429–444.
26. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3 α regulates production of Alzheimer's disease amyloid- β peptides. *Nature* 2003;423:435–439.
27. Kaytor MD, Orr HT. The GSK3 β signaling cascade and neurodegenerative disease. *Curr Opin Neurobiol* 2002;12:275–278.
28. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β -protein, and the β -amyloid precursor protein intracellular domain in vivo. *Proc Natl Acad Sci USA* 2003;100:4162–4167.
29. Vekrellis K, Ye Z, Qiu WQ, et al. Neurons regulate extracellular levels of amyloid β -protein via proteolysis by insulin-degrading enzyme. *J Neurosci* 2000;20:1657–1665.
30. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. *Trends Neurosci* 2000;23:542–549.
31. Craft S, Asthana S, Cook DG, et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. *Psychoneuroendocrinology* 2003;28:809–822.
32. Blass JP. Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. *Neurobiol Aging* 2002;23:1077–1084.
33. Heitner J, Dickson D. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects: a retrospective postmortem immunocytochemical and histofluorescent study. *Neurology* 1997;49:1306–1311.
34. Beeri MS, Silverman JM, Davis KL, et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. *J Gerontol A Biol Sci Med Sci* 2005;60:471–475.
35. Arvanitakis Z, Schneider JA, Wilson RS, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. *Neurology* 2006;67:1960–1965.
36. Yang DS, Small DH, Seydel U, et al. Apolipoprotein E promotes the binding and uptake of β -amyloid into Chinese hamster ovary cells in an isoform-specific manner. *Neuroscience* 1999;90:1217–1226.
37. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. *Brain Res* 1991;541:163–166.
38. Dolev I, Michaelson DM. A nontransgenic mouse model shows inducible amyloid- β (A β) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. *Proc Natl Acad Sci USA* 2004;101:13909–13914.

平成 22 年度厚生労働科学研究費補助金

循環器疾患・糖尿病等生活習慣病対策総合研究事業

「大規模コホートを用いた生活習慣病の一次予防のための運動量策定に関する運動疫学研究」

平成22年度総括・分担研究報告書

発行 平成23年(2011年) 3月

発行者 「大規模コホートを用いた生活習慣病の一次予防のための
運動量策定に関する運動疫学研究」班

班 長 熊谷 秋三

〒816-8580 春日市春日公園6-1

九州大学健康科学センター

TEL: 092-583-7853 FAX: 092-583-7853

印 刷 大和印刷 有限会社

〒812-0044 福岡市博多区千代2-4-31

TEL: 092-651-8578 FAX: 092-641-1514

